Tenax Therapeutics (TENX) Return on Capital Employed (2011 - 2026)
Tenax Therapeutics (TENX) reported Return on Capital Employed of 58.56% for Q1 2026, down 3207.0% on a YoY basis from 1.88% in Q1 2025, and little changed sequentially from 58.51% in Q4 2025.
Tenax Therapeutics (TENX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Tenax Therapeutics (TENX) has 14 years of Return on Capital Employed data on file, last reported at 58.56% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3207.0% year-over-year to 58.56%; the trailing twelve-month figure through Mar 2026 stood at 58.56% (down 3207.0% YoY), and the FY2025 full-year result was 60.43%, down 2105.0% from the prior year.
- Return on Capital Employed held at 58.56% in Q1 2026, from 58.51% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 496.95% in Q4 2022 to a low of 1861.13% in Q1 2022.
- A 5-year average of 235.56% and a median of 48.33% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 258417 bps in 2022 and jumped 194246 bps in 2023, its largest moves.
- Tracing TENX's Return on Capital Employed over 5 years: stood at 496.95% in 2022, then plunged by 128 bps to 137.96% in 2023, then soared by 85 bps to 20.84% in 2024, then sank by 181 bps to 58.51% in 2025, then fell by 0 bps to 58.56% in 2026.
- Business Quant data shows TENX's Return on Capital Employed at 58.56% in Q1 2026, 58.51% in Q4 2025, and 48.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Tenax Therapeutics | 655.78 Mn | 655.78 Mn | - | -58.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.56% |
| Dec 31, 2025 | -58.51% |
| Sep 30, 2025 | -48.33% |
| Jun 30, 2025 | -32.93% |
| Mar 31, 2025 | -26.50% |
| Dec 31, 2024 | -20.84% |
| Sep 30, 2024 | -48.11% |
| Jun 30, 2024 | -172.16% |
| Mar 31, 2024 | -123.91% |
| Dec 31, 2023 | -137.96% |
| Sep 30, 2023 | 35.33% |
| Jun 30, 2023 | 37.36% |
| Mar 31, 2023 | 81.33% |
| Dec 31, 2022 | 496.95% |
| Sep 30, 2022 | -917.58% |
| Jun 30, 2022 | -1,148.98% |
| Mar 31, 2022 | -1,861.13% |
| Dec 31, 2021 | -555.85% |
| Sep 30, 2021 | 729.09% |
| Jun 30, 2021 | 1,207.78% |